ScholarIQanswers from OpenAlex & ORCID
Aimery de Gramont
ResearcherPublications, citations & collaboration network
Aimery de Gramont is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Aimery de Gramont have?
ScholarIQindexed works
Aimery de Gramont has 595 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Aimery de Gramont have?
ScholarIQcitation count
Aimery de Gramont has 36,766 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Aimery de Gramont?
ScholarIQh-index
Aimery de Gramont has an h-index of 79 in OpenAlex.
What is the i10-index of Aimery de Gramont?
ScholarIQi10-index
Aimery de Gramont has an i10-index of 227 in OpenAlex.
What is the ORCID of Aimery de Gramont?
ScholarIQorcid
The ORCID for Aimery de Gramont is on the source record.
What is the OpenAlex record for Aimery de Gramont?
ScholarIQopenalex
The OpenAlex for Aimery de Gramont is on the source record.
What are the most-cited papers on Aimery de Gramont?
ScholarIQmost cited works
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
F. Huguet, Thierry André, Pascal Hammel, Pascal Artru, Jacques Balosso, Frédèric Selle, Élisabeth Deniaud-Alexandre, Philippe Ruszniewski, E. Touboul, Roberto Labianca, Aimery de Gramont, Christophe Louvet
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Gérard Lledo, Laurent Mineur, Thierry André, Mostepha Bennamoun, May Mabro, Pascal Artru, Élisabeth Carola, M. Flesch, Olivier Dupuis, Philippe Colin, Annette K. Larsen, Pauline Afchain, Christophe Tournigand, Christophe Louvet, Aimery de Gramont
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André, Déwi Vernerey, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Serge Fratté, Marine Hug de Larauze, Sophie Paget‐Bailly, Benoist Chibaudel, Jérémie Bez, Jérôme Dauba, Christophe Louvet, Céline Lepère, Olivier Dupuis, Y. Bécouarn, May Mabro, Joëlle Egreteau, Olivier Bouché, G. Deplanque, Marc Ychou, Marie Pierre Galais, François Ghiringhelli, Louis Marie Dourthe, Jean‐Baptiste Bachet, Ahmed Khalil, Franck Bonnetain, Aimery de Gramont, Julien Taı̈eb, for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER